The Exosomes Market size was estimated USD 113.3 million in 2022 and is expected to reach USD 1076.35 million by 2030 at a CAGR of 32.5% during the forecast period of 2023-2030.
Exosomes are Extracellular Vesicles (EVs) that are enclosed in a single outer membrane. They are found in saliva, urine, plasma, sperm, breast milk, Cerebral Spinal Fluid (CSF), amniotic fluid, bronchial fluid, bile, lymph, serum, stomach acid, synovial fluid, and tears. These vesicles transport proteins and genetic information throughout the body and serve as conduits for cell communication.
DRIVERS
Increasing prevalence of cancer globally
The increasing prevalence of cancer worldwide is a major factor driving market expansion. According to the American Cancer Society, by the end of 2022, there will be an estimated 1.9 million new cancer diagnoses and 609,360 cancer deaths. As a result, exosomes carry a wide cargo of molecules, such as proteins, nucleic acids, and lipids, which can act as biomarkers for various cancer types. They can be designed to transport therapeutic payloads like chemotherapeutic medicines, short RNAs, or immune-stimulating chemicals.
Increase in government and non-government activities for exosome research
RESTRAIN
A significant barrier in the exosome market is a lack of standards.
The field of exosome research and applications has expanded rapidly, but it is hampered by a lack of standardized protocols, methods, and characterisation approaches. Different methods of isolation and purification can result in exosomes with varied properties, making it difficult to compare results across investigations. Standardized isolation techniques are required to guarantee uniform and repeatable findings.
OPPORTUNITY
Rising demand for specialized testing services among end users
In recent years, cooperating sooner in the drug development process to improve efficiencies has become an increasing trend. Specialized testing services include Liquid Chromatography-Mass Spectrometry (LC/MS), RNA sequencing, gene expression analysis, compendia raw material wet chemical analysis, and trace metal analysis using Inductively Coupled Mass Spectrometry (ICP-MS), and others are increasingly being outsourced much earlier in the API process development cycle. These specialist services are mostly employed for the structural elucidation of critical impurities, the removal of class | and II solvents, risks analysis, column chromatography removal, and efforts toward overall cost reduction and process efficiency.
CHALLENGE
There are no gold standard methodologies for the production of exosomes.
Exosome research is still in its early phases, with no gold standards in place. As a result, professionals often adapt new tactics and ideas introduced into the market. Exosome research, development, and manufacturing present researchers with a variety of challenges.
Costs and price variations of APIs and raw materials continue to be key difficulties for pharmaceutical businesses and contract manufacturing organizations, which have been worsened by the Ukraine crisis. Pharma firms can minimize some of the effects of API and raw material costs, as well as pricing and availability, with a unified supply chain platform, which includes demand sensing capabilities, live market indices and projections to spot and leverage prices, and cost-cutting possibilities.
IMPACT OF ONGOING RECESSION
Recession might reduced healthcare sector profits by more than $70.0 billion in 2022. While numerous variables will contribute to this loss, supply chain interruptions are one of them. A shortage of foreign shipping is pushing providers to negotiate with untrustworthy suppliers and handle price demands for specialty medical items. As a result, medical supply prices increased by 46% last year, exceeding growth in labor costs. Increasing energy prices. The Ukraine conflict has resulted in higher transportation prices, which suppliers are now passing on to providers, as well as labor difficulties.
By Product
Kits & Reagents
Instruments
Services
In 2022, Kits & Reagents segment is expected to held the highest market share of 44.9% during the forecast period. To widen the applications of exosomes, key firms are developing novel kits and reagents. Clara Biotech, for example, launched an ExoRelease starter kit for exosome extraction and purification in May 2022. These technical breakthroughs enable researchers to analyze novel biomarkers in order to explore and develop exosome-based therapies and diagnostic applications. As a result, such innovations are expected to boost segment growth in the next years.
By Workflow
Isolation Methods
Ultracentrifugation
Immunocapture on beads
Precipitation
Filtration
Others
Downstream Analysis
Cell surface marker analysis using flow cytometry
Protein analysis using blotting & ELISA
RNA analysis with NGS & PCR
Proteomic analysis using mass spectroscopy
Others
In 2022, Downstream Analysis segment is expected to held the highest market share of 58.5% during the forecast period. Exosome detection, quantification, labeling, and modification or engineering are all part of the downstream analysis. These procedures may necessitate advanced sample preparation, downstream data interpretation, and the application of analytical techniques such as RNA sequencing and mass spectrometry for proteome analysis. Major businesses are delivering a variety of technologically advanced downstream analysis products. System Biosciences' Exo-ELISA Ultra technique, for example, measures exosomes in 4 hours using micro samples. As a result, the increased efficiency and utility of advanced downstream analysis methodologies is helping to drive segment growth. Over the forecast period, the isolation methods segment is expected to increase at a profitable CAGR.
By Application
Cancer
Neurodegenerative diseases
Cardiovascular diseases
Infectious diseases
Others
In 2022, the Cancer segment is expected to dominate the market growth of 31.9% during the forecast period due to the numerous applications of exosomes in cancer diagnosis, prognosis, and treatment. Exosomes have the potential to be exploited for high-efficiency therapeutic delivery of RNAs, small compounds, and proteins to cancer cells. Furthermore, lipids, proteins, and nucleic acids carried by exosomes are being investigated as potential cancer therapeutic targets as well as promising biomarkers for cancer diagnosis and prognosis. The rising prevalence of cancer and the increasing demand for early identification of the disease are projected to drive growth in the category in the near future.
By End User
Pharmaceutical & biotechnology companies
Hospitals & diagnostics centers
Academic & research institutes
.png)
In 2022, Pharmaceutical and biotechnology companies segment is expected to dominate the market growth of 49.5% during the forecast period owing to the rising demand for extracellular vesicle-based medicines and vaccines. Furthermore, various pharmaceutical and biotechnology businesses are forming alliances and collaborations to improve large-scale production. For example, in January 2023, Sartorius AG announced a collaboration with RoosterBio to develop downstream purification methods for exosome synthesis. Similarly, Sartorius BIA Separations and Exopharm formed a partnership in November 2022 to improve large-scale medicinal exosome production and commercialization.
North America held a significant market share growing with a CAGR of 55.3% in 2022 due to increased government financing for the discovery of novel biomarkers and the prevalence of chronic diseases such as cardiovascular disease and cancer is increasing. Furthermore, increased R&D initiatives for the development of novel medications, diagnostic procedures, and treatment choices are expected to fuel segment growth. Furthermore, the presence of significant key players in the region, such as Bio-Techne Corp., Hologic Inc., and Danaher Corp., is expected to stimulate growth.
Europe is witness to expand fastest CAGR rate of 16.2% during the forecast period owing to the increasing number of public and private joint efforts has resulted in ongoing market growth. The German Society for Extracellular Vesicles, for example, is a network of exosome-related experts. The society promotes collaborative research and assists young academics working in the topic of exosomes in the region. Such activities are projected to boost the market's long-term growth potential.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Danaher Corp., Hologic Inc., Fujifilm Holdings Corp., Lonza, Miltenyi Biotec, Bio-Techne Corp., QIAGEN, Thermo Fisher Scientific, Inc., Abcam plc, RoosterBio, Inc., Codiak BioSciences, and Others.
In May 2022, Clara Biotech has released an ExoRelease starter kit for isolating and purifying exosomes. With the use of such highly advanced items, exosome-based therapeutics and diagnostic applications can be studied and improved. This technique aided the corporation in expanding its product portfolio.
In November 2021, Codiak BioSciences, a clinical-stage biopharmaceutical firm pioneering the development of exosome-based therapies, has sold its exosome manufacturing facility in Lexington, Massachusetts (US) to Lonza. This enabled the corporation to expand its services and make more income.
|
Report Attributes |
Details |
|
Market Size in 2022 |
US$ 113.3 million |
|
Market Size by 2030 |
US$ 1076.35 million |
|
CAGR |
CAGR of 32.5% From 2023 to 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023-2030 |
|
Historical Data |
2019-2021 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
By Product (Kits & Reagents, Instruments, Services), By Workflow (Isolation Methods, Downstream Analysis), By Application (Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Others), By End User (Pharmaceutical & biotechnology companies, Hospitals & diagnostics centers, Academic & research institutes) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
|
Company Profiles |
Danaher Corp., Hologic Inc., Fujifilm Holdings Corp., Lonza, Miltenyi Biotec, Bio-Techne Corp., QIAGEN, Thermo Fisher Scientific, Inc., Abcam plc, RoosterBio, Inc., Codiak BioSciences |
|
Key Drivers |
•Increase in government and non-government activities for exosome research •Increasing prevalence of cancer globally |
|
Market Challenges |
•There are no gold standard methodologies for the production of exosomes |
Yes, you may request customization based on your company's needs.
Growth in government and non-government initiatives for exosome research.
Exosomes Market size was valued at USD 113.3 million in 2022.
According to our analysis, the Exosomes Market is anticipated to reach USD 1076.35 million By 2030.
The Exosomes Market is expected to grow at 32.5% CAGR from 2023 to 2030.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Exosomes Market Segmentation, by Product
8.1 Kits & Reagents
8.2 Instruments
8.3 Services
9. Exosomes Market Segmentation, by Workflow
9.1 Isolation Methods
9.1.1 Ultracentrifugation
9.1.2 Immunocapture on beads
9.1.3 Precipitation
9.1.4 Filtration
9.1.5 Others
9.2 Downstream Analysis
9.2.1 Cell surface marker analysis using flow cytometry
9.2.2 Protein analysis using blotting & ELISA
9.2.3 RNA analysis with NGS & PCR
9.2.4 Proteomic analysis using mass spectroscopy
9.2.5 Others
10. Exosomes Market Segmentation, by Application
10.1 Cancer
10.2 Neurodegenerative diseases
10.3 Cardiovascular diseases
10.4 Infectious diseases
10.5 Others
11. Exosomes Market Segmentation, by End User
11.1 Pharmaceutical & biotechnology companies
11.2 Hospitals & diagnostics centers
11.3 Academic & research institutes
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Exosomes Market by Country
12.2.2North America Exosomes Market by Product
12.2.3 North America Exosomes Market by Workflow
12.2.4 North America Exosomes Market by Application
12.2.5 North America Exosomes Market by End User
12.2.6 USA
12.2.6.1 USA Exosomes Market by Product
12.2.6.2 USA Exosomes Market by Workflow
12.2.6.3 USA Exosomes Market by Application
12.2.6.4 USA Exosomes Market by End User
12.2.7 Canada
12.2.7.1 Canada Exosomes Market by Product
12.2.7.2 Canada Exosomes Market by Workflow
12.2.7.3 Canada Exosomes Market by Application
12.2.7.4 Canada Exosomes Market by End User
12.2.8 Mexico
12.2.8.1 Mexico Exosomes Market by Product
12.2.8.2 Mexico Exosomes Market by Workflow
12.2.8.3 Mexico Exosomes Market by Application
12.2.8.4 Mexico Exosomes Market by End User
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Exosomes Market by Country
12.3.1.2 Eastern Europe Exosomes Market by Product
12.3.1.3 Eastern Europe Exosomes Market by Workflow
12.3.1.4 Eastern Europe Exosomes Market by Application
12.3.1.5 Eastern Europe Exosomes Market by End User
12.3.1.6 Poland
12.3.1.6.1 Poland Exosomes Market by Product
12.3.1.6.2 Poland Exosomes Market by Workflow
12.3.1.6.3 Poland Exosomes Market by Application
12.3.1.6.4 Poland Exosomes Market by End User
12.3.1.7 Romania
12.3.1.7.1 Romania Exosomes Market by Product
12.3.1.7.2 Romania Exosomes Market by Workflow
12.3.1.7.3 Romania Exosomes Market by Application
12.3.1.7.4 Romania Exosomes Market by End User
12.3.1.8 Hungary
12.3.1.8.1 Hungary Exosomes Market by Product
12.3.1.8.2 Hungary Exosomes Market by Workflow
12.3.1.8.3 Hungary Exosomes Market by Application
12.3.1.8.4 Hungary Exosomes Market by End User
12.3.1.9 Turkey
12.3.1.9.1 Turkey Exosomes Market by Product
12.3.1.9.2 Turkey Exosomes Market by Workflow
12.3.1.9.3 Turkey Exosomes Market by Application
12.3.1.9.4 Turkey Exosomes Market by End User
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Exosomes Market by Product
12.3.1.10.2 Rest of Eastern Europe Exosomes Market by Workflow
12.3.1.10.3 Rest of Eastern Europe Exosomes Market by Application
12.3.1.10.4 Rest of Eastern Europe Exosomes Market by End User
12.3.2 Western Europe
12.3.2.1 Western Europe Exosomes Market by Country
12.3.2.2 Western Europe Exosomes Market by Product
12.3.2.3 Western Europe Exosomes Market by Workflow
12.3.2.4 Western Europe Exosomes Market by Application
12.3.2.5 Western Europe Exosomes Market by End User
12.3.2.6 Germany
12.3.2.6.1 Germany Exosomes Market by Product
12.3.2.6.2 Germany Exosomes Market by Workflow
12.3.2.6.3 Germany Exosomes Market by Application
12.3.2.6.4 Germany Exosomes Market by End User
12.3.2.7 France
12.3.2.7.1 France Exosomes Market by Product
12.3.2.7.2 France Exosomes Market by Workflow
12.3.2.7.3 France Exosomes Market by Application
12.3.2.7.4 France Exosomes Market by End User
12.3.2.8 UK
12.3.2.8.1 UK Exosomes Market by Product
12.3.2.8.2 UK Exosomes Market by Workflow
12.3.2.8.3 UK Exosomes Market by Application
12.3.2.8.4 UK Exosomes Market by End User
12.3.2.9 Italy
12.3.2.9.1 Italy Exosomes Market by Product
12.3.2.9.2 Italy Exosomes Market by Workflow
12.3.2.9.3 Italy Exosomes Market by Application
12.3.2.9.4 Italy Exosomes Market by End User
12.3.2.10 Spain
12.3.2.10.1 Spain Exosomes Market by Product
12.3.2.10.2 Spain Exosomes Market by Workflow
12.3.2.10.3 Spain Exosomes Market by Application
12.3.2.10.4 Spain Exosomes Market by End User
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Exosomes Market by Product
12.3.2.11.2 Netherlands Exosomes Market by Workflow
12.3.2.11.3 Netherlands Exosomes Market by Application
12.3.2.11.4 Netherlands Exosomes Market by End User
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Exosomes Market by Product
12.3.2.12.2 Switzerland Exosomes Market by Workflow
12.3.2.12.3 Switzerland Exosomes Market by Application
12.3.2.12.4 Switzerland Exosomes Market by End User
12.3.2.13 Austria
12.3.2.13.1 Austria Exosomes Market by Product
12.3.2.13.2 Austria Exosomes Market by Workflow
12.3.2.13.3 Austria Exosomes Market by Application
12.3.2.13.4 Austria Exosomes Market by End User
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Exosomes Market by Product
12.3.2.14.2 Rest of Western Europe Exosomes Market by Workflow
12.3.2.14.3 Rest of Western Europe Exosomes Market by Application
12.3.2.14.4 Rest of Western Europe Exosomes Market by End User
12.4 Asia-Pacific
12.4.1 Asia Pacific Exosomes Market by Country
12.4.2 Asia Pacific Exosomes Market by Product
12.4.3 Asia Pacific Exosomes Market by Workflow
12.4.4 Asia Pacific Exosomes Market by Application
12.4.5 Asia Pacific Exosomes Market by End User
12.4.6 China
12.4.6.1 China Exosomes Market by Product
12.4.6.2 China Exosomes Market by Workflow
12.4.6.3 China Exosomes Market by Application
12.4.6.4 China Exosomes Market by End User
12.4.7 India
12.4.7.1 India Exosomes Market by Product
12.4.7.2 India Exosomes Market by Workflow
12.4.7.3 India Exosomes Market by Application
12.4.7.4 India Exosomes Market by End User
12.4.8 Japan
12.4.8.1 Japan Exosomes Market by Product
12.4.8.2 Japan Exosomes Market by Workflow
12.4.8.3 Japan Exosomes Market by Application
12.4.8.4 Japan Exosomes Market by End User
12.4.9 South Korea
12.4.9.1 South Korea Exosomes Market by Product
12.4.9.2 South Korea Exosomes Market by Workflow
12.4.9.3 South Korea Exosomes Market by Application
12.4.9.4 South Korea Exosomes Market by End User
12.4.10 Vietnam
12.4.10.1 Vietnam Exosomes Market by Product
12.4.10.2 Vietnam Exosomes Market by Workflow
12.4.10.3 Vietnam Exosomes Market by Application
12.4.10.4 Vietnam Exosomes Market by End User
12.4.11 Singapore
12.4.11.1 Singapore Exosomes Market by Product
12.4.11.2 Singapore Exosomes Market by Workflow
12.4.11.3 Singapore Exosomes Market by Application
12.4.11.4 Singapore Exosomes Market by End User
12.4.12 Australia
12.4.12.1 Australia Exosomes Market by Product
12.4.12.2 Australia Exosomes Market by Workflow
12.4.12.3 Australia Exosomes Market by Application
12.4.12.4 Australia Exosomes Market by End User
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Exosomes Market by Product
12.4.13.2 Rest of Asia-Pacific Exosomes Market by Workflow
12.4.13.3 Rest of Asia-Pacific Exosomes Market by Application
12.4.13.4 Rest of Asia-Pacific Exosomes Market by End User
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Exosomes Market by country
12.5.1.2 Middle East Exosomes Market by Product
12.5.1.3 Middle East Exosomes Market by Workflow
12.5.1.4 Middle East Exosomes Market by Application
12.5.1.5 Middle East Exosomes Market by End User
12.5.1.6 UAE
12.5.1.6.1 UAE Exosomes Market by Product
12.5.1.6.2 UAE Exosomes Market by Workflow
12.5.1.6.3 UAE Exosomes Market by Application
12.5.1.6.4 UAE Exosomes Market by End User
12.5.1.7 Egypt
12.5.1.7.1 Egypt Exosomes Market by Product
12.5.1.7.2 Egypt Exosomes Market by Workflow
12.5.1.7.3 Egypt Exosomes Market by Application
12.5.1.7.4 Egypt Exosomes Market by End User
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Exosomes Market by Product
12.5.1.8.2 Saudi Arabia Exosomes Market by Workflow
12.5.1.8.3 Saudi Arabia Exosomes Market by Application
12.5.1.8.4 Saudi Arabia Exosomes Market by End User
12.5.1.9 Qatar
12.5.1.9.1 Qatar Exosomes Market by Product
12.5.1.9.2 Qatar Exosomes Market by Workflow
12.5.1.9.3 Qatar Exosomes Market by Application
12.5.1.9.4 Qatar Exosomes Market by End User
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Exosomes Market by Product
12.5.1.10.2 Rest of Middle East Exosomes Market by Workflow
12.5.1.10.3 Rest of Middle East Exosomes Market by Application
12.5.1.10.4 Rest of Middle East Exosomes Market by End User
12.5.2. Africa
12.5.2.1 Africa Exosomes Market by country
12.5.2.2 Africa Exosomes Market by Product
12.5.2.3 Africa Exosomes Market by Workflow
12.5.2.4 Africa Exosomes Market by Application
12.5.2.5 Africa Exosomes Market by End User
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Exosomes Market by Product
12.5.2.6.2 Nigeria Exosomes Market by Workflow
12.5.2.6.3 Nigeria Exosomes Market by Application
12.5.2.6.4 Nigeria Exosomes Market by End User
12.5.2.7 South Africa
12.5.2.7.1 South Africa Exosomes Market by Product
12.5.2.7.2 South Africa Exosomes Market by Workflow
12.5.2.7.3 South Africa Exosomes Market by Application
12.5.2.7.4 South Africa Exosomes Market by End User
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Exosomes Market by Product
12.5.2.8.2 Rest of Africa Exosomes Market by Workflow
12.5.2.8.3 Rest of Africa Exosomes Market by Application
12.5.2.8.4 Rest of Africa Exosomes Market by End User
12.6. Latin America
12.6.1 Latin America Exosomes Market by country
12.6.2 Latin America Exosomes Market by Product
12.6.3 Latin America Exosomes Market by Workflow
12.6.4 Latin America Exosomes Market by Application
12.6.5 Latin America Exosomes Market by End User
12.6.6 Brazil
12.6.6.1 Brazil Exosomes Market by Product
12.6.6.2 Brazil Exosomes Market by Workflow
12.6.6.3 Brazil Exosomes Market by Application
12.6.6.4 Brazil Exosomes Market by End User
12.6.7 Argentina
12.6.7.1 Argentina Exosomes Market by Product
12.6.7.2 Argentina Exosomes Market by Workflow
12.6.7.3 Argentina Exosomes Market by Application
12.6.7.4 Argentina Exosomes Market by End User
12.6.8 Colombia
12.6.8.1 Colombia Exosomes Market by Product
12.6.8.2 Colombia Exosomes Market by Workflow
12.6.8.3 Colombia Exosomes Market by Application
12.6.8.4 Colombia Exosomes Market by End User
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Exosomes Market by Product
12.6.9.2 Rest of Latin America Exosomes Market by Workflow
12.6.9.3 Rest of Latin America Exosomes Market by Application
12.6.9.4 Rest of Latin America Exosomes Market by End User
13 Company Profile
13.1 Danaher Corp.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Hologic Inc.
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Fujifilm Holdings Corp.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Lonza
13.4 Company Overview
13.4.2 Financials
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Miltenyi Biotec
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Bio-Techne Corp.
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 QIAGEN
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Thermo Fisher Scientific, Inc.
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Abcam plc
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 RoosterBio, Inc.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
13.11 Codiak BioSciences
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
13.12 Others
14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Downstream Processing Market Size was valued at USD 28.24 billion in 2022, and is expected to reach USD 80.01 billion by 2030 and grow at a CAGR of 13.9% over the forecast period 2023-2030.
The Microtome Market size was estimated USD 428.0 Million in 2022 and is expected to reach USD 724.4 Million by 2030 at a CAGR of 6.8% during the forecast period of 2023 to 2030.
The Healthcare Business Intelligence (BI) Market Size was valued at USD 8.8 billion in 2023, and is expected to reach USD 24.57 billion by 2031, and grow at a CAGR of 13.7% over the forecast period 2024-2031.
The Medical Device Cleaning Market Size was valued at USD 2.35 billion in 2023 and is expected to reach USD 3.49 billion by 2031, and grow at a CAGR of 5.75% over the forecast period 2024-2031.
The Human Insulin Market size was valued at USD 19.21 billion in 2023 and is expected to reach USD 24.71 billion by 2031 and grow at a CAGR of 3.2% over the forecast period of 2024-2031.
The Process Analytical Technology Market size was estimated USD 3.2 billion in 2022 and is expected to reach USD 7.1 billion by 2030 at a CAGR of 10.5% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
